Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab
Our findings indicate that the AEs associated with dual ICI predominantly originate from immune-related AEs, including myotoxicity, endocrine toxicity, and hepatotoxicity. Notably, cytokine release syndrome, a rarely reported AE with a strongly positive signal, warrants particular attention in clinical decision-making.
Authors
- Zhuoyang Li (ORCID: https://orcid.org/0009-0003-1631-3634)
- Tianhong Wang (ORCID: https://orcid.org/0000-0002-0331-3761)
- Yusi Hua (ORCID: https://orcid.org/0000-0003-1640-8388)
- Yuwei Liu (ORCID: https://orcid.org/0009-0005-7178-3895)
- Ye Tian (ORCID: https://orcid.org/0000-0001-6080-1289)
- Yinghong Xie
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Wuhan University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1631273
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05